Chasing 'Holy Grail' STAT3 target, Houston startup refuels with $74M to zero in on liver cancer
Tvardi launched out of Houston with the promise of finally developing the right inhibitors for the Holy Grail target of STAT3 — under the guidance …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
